Table 2.
Assessment of the influence of Ro-61-8048 treatment on the severity of the late CNS stage neuropathological response
| I − D + Ro | I − D | I − D + V | U − D + Ro | |
|---|---|---|---|---|
| I – D | P=0.0284 (0.062, 1.272) | |||
| I – D + V | P=0.0385 (0.032, 1.385) | P=0.9979 (−0.635, 0.718) | ||
| U − D + Ro | P<0.0001 (−3.533, −2.051) | P<0.0001 (2.717, 4.199) | P<0.0001 (2.700, 4.300) | |
| Mean±SE | 2.792±0.100 | 3.458±0.187 | 3.500±0.228 | 0.000±0.000 |
| Number | 6 | 6 | 4 | 3 |
The neuropathology scores were measured in mice infected (I) with T. b. brucei and treated with Ro-61-8048 (Ro) or vehicle (V). Uninfected (U), Ro-61-8048 treated mice were assessed in parallel with the infected animals. All animals were treated with diminazene aceturate (D) on Day 21 post-infection to induce a late-stage response. The mean score and standard error (Mean ± SE) together with the number of animals in each group are detailed. The figures in the body of the table demonstrate the comparisons, in terms of statistical significance, between the groups shown in the row and column headings. The 95% CIs for the differences between the group means are given along with the P-values.